Shenzhen Neptunus Interlong Bio-technique Company Limited (8329.HK)
HKD 0.14
(1.41%)
HKD 0.14
(1.41%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 3.77 Million CNY | -15.9% |
| 2022 | 4.48 Million CNY | 623.06% |
| 2021 | 620 Thousand CNY | 0.0% |
| 2020 | - CNY | -100.0% |
| 2019 | 2.57 Million CNY | 0.0% |
| 2018 | - CNY | 0.0% |
| 2017 | - CNY | 0.0% |
| 2016 | - CNY | 0.0% |
| 2015 | - CNY | 0.0% |
| 2014 | - CNY | -100.0% |
| 2013 | 138.09 Million CNY | 0.0% |
| 2012 | - CNY | 0.0% |
| 2011 | - CNY | -100.0% |
| 2010 | 62 Million CNY | -27.91% |
| 2009 | 86 Million CNY | -53.26% |
| 2008 | 184 Million CNY | 53.33% |
| 2007 | 120 Million CNY | -5.51% |
| 2006 | 127 Million CNY | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 5.61 Million CNY | 0.0% |
| 2024 Q1 | - CNY | -100.0% |
| 2023 Q2 | 6.36 Million CNY | 0.0% |
| 2023 Q4 | 3.77 Million CNY | 0.0% |
| 2023 Q3 | - CNY | -100.0% |
| 2023 FY | 3.77 Million CNY | -15.9% |
| 2023 Q1 | - CNY | -100.0% |
| 2022 Q2 | 4.19 Million CNY | 0.0% |
| 2022 Q4 | 4.48 Million CNY | 0.0% |
| 2022 FY | 4.48 Million CNY | 623.06% |
| 2022 Q1 | - CNY | -100.0% |
| 2022 Q3 | - CNY | -100.0% |
| 2021 Q2 | 113.32 Million CNY | 0.0% |
| 2021 Q1 | - CNY | 0.0% |
| 2021 FY | 620 Thousand CNY | 0.0% |
| 2021 Q4 | 620 Thousand CNY | 0.0% |
| 2020 Q2 | - CNY | 0.0% |
| 2020 FY | - CNY | -100.0% |
| 2020 Q1 | - CNY | -100.0% |
| 2020 Q4 | - CNY | 0.0% |
| 2019 Q1 | - CNY | 0.0% |
| 2019 Q2 | 3.22 Million CNY | 0.0% |
| 2019 Q4 | 2.57 Million CNY | 0.0% |
| 2019 FY | 2.57 Million CNY | 0.0% |
| 2018 Q2 | - CNY | 0.0% |
| 2018 FY | - CNY | 0.0% |
| 2018 Q4 | - CNY | 0.0% |
| 2018 Q1 | - CNY | 0.0% |
| 2017 Q2 | - CNY | 0.0% |
| 2017 Q1 | - CNY | 0.0% |
| 2017 FY | - CNY | 0.0% |
| 2017 Q4 | - CNY | 0.0% |
| 2016 Q4 | - CNY | 0.0% |
| 2016 Q1 | - CNY | 0.0% |
| 2016 FY | - CNY | 0.0% |
| 2016 Q2 | - CNY | 0.0% |
| 2015 Q2 | - CNY | 0.0% |
| 2015 Q4 | - CNY | 0.0% |
| 2015 Q1 | - CNY | 0.0% |
| 2015 FY | - CNY | 0.0% |
| 2014 FY | - CNY | -100.0% |
| 2014 Q2 | - CNY | 0.0% |
| 2014 Q4 | - CNY | 0.0% |
| 2014 Q1 | - CNY | -100.0% |
| 2013 Q2 | - CNY | 0.0% |
| 2013 FY | 138.09 Million CNY | 0.0% |
| 2013 Q4 | 138.09 Million CNY | 0.0% |
| 2013 Q1 | - CNY | 0.0% |
| 2012 FY | - CNY | 0.0% |
| 2012 Q4 | - CNY | 0.0% |
| 2012 Q2 | - CNY | 0.0% |
| 2011 Q2 | - CNY | 0.0% |
| 2011 Q4 | - CNY | 0.0% |
| 2011 FY | - CNY | -100.0% |
| 2010 Q2 | 152 Million CNY | 0.0% |
| 2010 FY | 62 Million CNY | -27.91% |
| 2010 Q4 | 62 Million CNY | 0.0% |
| 2009 Q4 | 86 Million CNY | 0.0% |
| 2009 FY | 86 Million CNY | -53.26% |
| 2008 FY | 184 Million CNY | 53.33% |
| 2007 FY | 120 Million CNY | -5.51% |
| 2006 FY | 127 Million CNY | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 2.07 Million HKD | -81.862% |
| Grand Pharmaceutical Group Limited | 990.02 Million HKD | 99.619% |
| Extrawell Pharmaceutical Holdings Limited | 117.12 Million HKD | 96.781% |
| Wai Yuen Tong Medicine Holdings Limited | 276.2 Million HKD | 98.635% |
| Qianhai Health Holdings Limited | - HKD | -Infinity% |
| Lee's Pharmaceutical Holdings Limited | 70.63 Million HKD | 94.663% |
| Essex Bio-Technology Limited | 36.05 Million HKD | 89.544% |
| Tongfang Kontafarma Holdings Limited | 12.8 Million HKD | 70.549% |
| PuraPharm Corporation Limited | 81.09 Million HKD | 95.351% |
| SSY Group Limited | 1.94 Billion HKD | 99.806% |
| JBM (Healthcare) Limited | 43.8 Million HKD | 91.393% |
| Jacobson Pharma Corporation Limited | 592.2 Million HKD | 99.363% |
| China Resources Pharmaceutical Group Limited | 16.61 Billion HKD | 99.977% |